Cefotaxime
From Wikipedia, the free encyclopedia
Cefotaxime
|
|
Systematic (IUPAC) name | |
(6R,7R,Z)-3-(acetoxymethyl)-7-(2-(2-aminothiazol-4-yl)- 2-(methoxyimino)acetamido)-8-oxo-5-thia-1-azabicyclo[4.2.0] oct-2-ene-2-carboxylic acid |
|
Identifiers | |
CAS number | |
ATC code | J01 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | C16H17N5O7S2 |
Mol. mass | 455.47 g/mol |
Pharmacokinetic data | |
Bioavailability | n/a |
Metabolism | Hepatic |
Half life | 0.8–1.4 hours |
Excretion | 50–85% renal |
Therapeutic considerations | |
Pregnancy cat. | |
Legal status | |
Routes | Intravenous |
Cefotaxime (INN) (IPA: [kɛfəˈtæksim, sɛfə-]) is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium is marketed under various trade names including Claforan (Sanofi-Aventis).
[edit] Clinical use
[edit] Chemistry
The syn-configuration of the methoxyimino moiety confers stability to β-lactamase enzymes produced by many Gram-negative bacteria. Such stability to β-lactamases increases the activity of cefotaxime against otherwise resistant Gram-negative organisms.
[edit] External links
|
|
---|---|
First Generation | Cefacetrile, Cefadroxil, Cefalexin, Cefaloglycin, Cefalonium, Cefaloridine, Cefalotin, Cefapirin, Cefatrizine, Cefazaflur, Cefazedone, Cefazolin, Cefradine, Cefroxadine, Ceftezole |
Second Generation | Cefaclor, Cefamandole, Cefonicid, Ceforanide, Cefotiam, Cefprozil, Cefuroxime, Cefuzonam |
Third Generation | Cefcapene, Cefdaloxime, Cefdinir, Cefditoren, Cefetamet, Cefixime, Cefmenoxime, Cefodizime, Cefoperazone, Cefotaxime, Cefpimizole, Cefpiramide, Cefpodoxime, Cefsulodin, Ceftazidime, Cefteram, Ceftibuten, Ceftiofur, Ceftiolene, Ceftizoxime, Ceftriaxone, Latamoxef |
Fourth Generation | Cefclidine, Cefepime, Cefetecol,Cefluprenam, Cefoselis, Cefozopran, Cefpirome, Cefquinome |